Glaxo Avoids Market for Lemons by Buying Collaborators

GlaxoSmithKline Plc may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.